A compound represented by Formula, an enantiomer, diastereomer, tautomer, solvate or pharmaceutical acceptable salt thereof wherein A and B are independently selected from 6- to 10-membered mono- or bicyclic aryl and 5- to 10-membered mono- or bicyclic heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S, wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, OH, CN, C 1-6 -alkyl, O-C 1-6 -alkyl, C OR a, OC R a, S -C 1-6 -alkyl, S 2 -C 1-6 -alkyl, N(R a) 2, C N(R a) 2, NR a C -C 1-6 -alkyl, S 2N(R a) 2, NR a S 2 -C 1-6 -alkyl and C 3-6 -cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-3 -alkyl, halo-C 1-3 -alkyl, OH, CN and oxo, or wherein two substituents on the aryl or heteroaryl group together with the atoms they are attached to may form a 5 to 7-membered saturated or partially unsaturated carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, N and S, wherein the carbocyclic or heterocyclic ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C 1-6 -alkyl and hafo-C 1-6 -alkyl; R 1, R 2, R 3 are each independently selected from hydrogen, halogen, C 1-3 -alkyl, halo-C 1-3 -alkyl, OH, O-C 1-3 -alkyl, and CN; R a is hydrogen or C 1-6 -alkyl; and R b is hydrogen or C 1-6 -alkyl. A and B are independently selected from 6- to 10-membered mono- or bicyclic aryl and 5- to 10-membered mono- or bicyclic heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S, wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, OH, CN, C 1-6 -alkyl, O-C 1-6 -alkyl, C OR a, OC R a, S -C 1-6 -alkyl, S 2 -C 1-6 -alkyl, N(R a) 2, C N(R a) 2, NR a C -C 1-6 -alkyl, S 2N(R a) 2, NR a S 2 -C 1-6 -alkyl and C 3-6 -cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-3 -alkyl, halo-C 1-3 -alkyl, OH, CN and oxo, or wherein two substituents on the aryl or heteroaryl group together with the atoms they are attached to may form a 5 to 7-membered saturated or partially unsaturated carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, N and S, wherein the carbocyclic or heterocyclic ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C 1-6 -alkyl and hafo-C 1-6 -alkyl; wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of halogen, OH, CN, C 1-6 -alkyl, O-C 1-6 -alkyl, C OR a, OC R a, S -C 1-6 -alkyl, S 2 -C 1-6 -alkyl, N(R a) 2, C N(R a) 2, NR a C -C 1-6 -alkyl, S 2N(R a) 2, NR a S 2 -C 1-6 -alkyl and C 3-6 -cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C 1-3 -alkyl, halo-C 1-3 -alkyl, OH, CN and oxo, or wherein two substituents on the aryl or heteroaryl group together with the atoms they are attached to may form a 5 to 7-membered saturated or partially unsaturated carbocyclic ring or heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, N and S, wherein the carbocyclic or heterocyclic ring is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, C 1-6 -alkyl and hafo-C 1-6 -alkyl; R 1, R 2, R 3 are each independently selected from hydrogen, halogen, C 1-3 -alkyl, halo-C 1-3 -alkyl, OH, O-C 1-3 -alkyl, and CN; R a is hydrogen or C 1-6 -alkyl; and R b is hydrogen or C 1-6 -alkyl.